Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection
Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™ a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™ (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI
Vital Proteins Proudly Announces Joining the Global B Corp Movement B Corporation™ certification will help further Vital Proteins’ efforts to make a positive impact on its community, workforce, customers and the planet
